Product Specification Sheet

Product Name: ABBV-744

Catalog Number: C2874



ABBV-744

Technical information:

Chemical Formula:	$C_{28}H_{30}FN_3O_4$
CAS #:	2138861-99-9
Molecular Weight:	491.55
Purity:	> 98%
Appearance:	Grey solid
Solubility:	Soluble in DMSO up to 200 mM
Chemical Name:	N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide
Storage:	For longer shelf life, store solid powder or DMSO solution at -20°C desiccated.
Shelf Life:	In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.

Handling:

- To make 10 mM stock solution, add 0.203mL of DMSO for each mg of ABBV-744.
- For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

Biological Activity:

ABBV-744 is a selective bromodomain and extra-terminal (BET) inhibitor that preferentially bind to the 2nd bromodomains (BD) than the 1st BD pf BET family proteins (i.e., BRD2. BRD3. BRD4) [1]. This selective targeting of BD2 subsets of the BET bromodomain abolished the broad antiproliferative activities for previous generation pan BET inhibitors, and only display antiproliferative activities in a limited number of cancer cell lines, including acute myeloid leukaemia and prostate cancer that expressed the full-length androgen receptor (AR) [2]. Improved tolerability is expected due to less impact on global transcription [3].

Reference:

1. Sheppard G, et al. Discovery of ABBV-744, a first-in-class highly BDII-selective BET bromodomain inhibitor. Cancer Res 2018; 78(Suppl):Abstract nr 931. Pubmed ID: DOI: 10.1158/1538-7445.AM2018-931

2. Faivre EJ, et al. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. Nature 2020; 578:306–310. Pubmed ID: 31969702
3. Lin X, et al. ABBV-744, a first-in-class and highly selective inhibitor of the second bromodomain of BET family proteins, displays robust activities in preclinical models of acute myelogenous leukemia. Cancer Res 2018;78(13 Suppl):Abstract nr 800. Pubmed ID: DOI: 10.1158/1538-7445.AM2018-800

To reorder: http://www.cellagentech.com/ABBV-744/

For Technical Support: technical@cellagentech.com

Chemicals are sold for research use only, not for clinical or diagnostic use.